<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="bor" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">bor</book-part-id>
      <title-group>
        <title>Branchiootorenal Spectrum Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Smith</surname>
            <given-names>Richard JH</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Director, Molecular Otolaryngology and Renal Research Laboratories<break/>Sterba Hearing Research Professor of Otolaryngology<break/>Professor of Otolaryngology, Pediatrics, and Internal Medicine, Division of Nephrology<break/>Carver College of Medicine<break/>University of Iowa<break/>Iowa City, Iowa</aff>
          <email>richard-smith@uiowa.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>19</day>
          <month>3</month>
          <year>1999</year>
        </date>
        <date date-type="updated">
          <day>22</day>
          <month>10</month>
          <year>2015</year>
        </date>
        <date date-type="revised">
          <day>27</day>
          <month>3</month>
          <year>2008</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="bofs" document-type="chapter">Branchiooculofacial Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="brugada" document-type="chapter">Brugada Syndrome</related-object>
      <abstract id="bor.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Branchiootorenal spectrum disorders comprise branchiootorenal (BOR) syndrome and branchiootic syndrome (BOS).</p>
          <list list-type="bullet">
            <list-item>
              <p>BOR is characterized by malformations of the outer, middle, and inner ear associated with conductive, sensorineural, or mixed hearing impairment, branchial fistulae and cysts, and renal malformations ranging from mild renal hypoplasia to bilateral renal agenesis. Some individuals progress to end-stage renal disease (ESRD) later in life.</p>
            </list-item>
            <list-item>
              <p>BOS has the same features as BOR syndrome but without renal involvement.</p>
            </list-item>
          </list>
          <p>Extreme variability can be observed in the presence, severity, and type of branchial arch, otologic, audiologic, and renal abnormality from right side to left side in an affected individual and also among individuals in the same family. BOR syndrome and BOS can be seen in the same family.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of branchiootorenal spectrum disorders is based on clinical criteria. Molecular genetic testing of <italic toggle="yes">EYA1</italic> (BOR1, BOS1) detects pathogenic variants in approximately 40% of individuals with the clinical diagnosis of BOR/BOS. Pathogenic variants can be detected in an additional 5% and 4% of individuals with the clinical diagnosis of BOR/BOS by molecular genetic testing of <italic toggle="yes">SIX5</italic> (BOR2) and <italic toggle="yes">SIX1</italic> (BOR3, BOS3), respectively.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Excision of branchial cleft cysts/fistulae, fitting with appropriate aural habilitation, and enrollment in appropriate educational programs for the hearing impaired are appropriate. A canaloplasty should be considered to correct an atretic external auditory canal. Medical and surgical treatment for vesicoureteral reflux may be necessary. End-stage renal disease (ESRD) may require dialysis or renal transplantation.</p>
          <p><italic toggle="yes">Surveillance:</italic> Semiannual examination for hearing impairment and annual audiometry to assess stability of hearing loss; monitoring of renal function to prevent progression to ESRD; semiannual/annual examination by a nephrologist and/or urologist, as indicated.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Nephrotoxic medications.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> At-risk relatives should be screened for hearing loss and renal involvement to allow for early diagnosis and treatment.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>BOR syndrome and BOS are inherited in an autosomal dominant manner. The offspring of an affected individual are at a 50% risk of inheriting the pathogenic variant. Prenatal testing for pregnancies at risk is possible if the pathogenic variant has been identified in a family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="bor.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="bor.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_bor.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">Branchiootorenal Spectrum Disorders: Included Phenotypes</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_bor.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">
                  <list list-type="bullet">
                    <list-item>
                      <p>Branchiootorenal (BOR) syndrome</p>
                    </list-item>
                    <list-item>
                      <p>Branchiootic syndrome (BOS)</p>
                    </list-item>
                  </list>
                </td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="bor.Nomenclature">Nomenclature</xref>.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="bor.Diagnosis">
        <title>Diagnosis</title>
        <p>Branchiootorenal spectrum disorders (BOR/BOS) comprise branchiootorenal (BOR) syndrome and branchiootic syndrome (BOS).</p>
        <sec id="bor.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Branchiootorenal spectrum disorders (BOR/BOS) <bold>should be suspected</bold> in individuals with the following characteristics:</p>
          <sec id="bor.Branchiootorenal_BOR_Syndrome">
            <title>Branchiootorenal (BOR) Syndrome</title>
            <p>In the absence of a family history, three or more of the following major criteria OR two major and two minor criteria (see <xref ref-type="table" rid="bor.T.major_and_minor_diagnostic_criteri">Table 1</xref>) must be present to make the clinical diagnosis of BOR syndrome [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>]:</p>
            <table-wrap id="bor.T.major_and_minor_diagnostic_criteri" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Major and Minor Diagnostic Criteria for Branchiootorenal Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_bor.T.major_and_minor_diagnostic_criteri_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Major Criteria</th>
                    <th id="hd_h_bor.T.major_and_minor_diagnostic_criteri_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Minor Criteria</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_bor.T.major_and_minor_diagnostic_criteri_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Second branchial arch anomalies<break/>Deafness<break/>Preauricular pits<break/>Auricular malformation<break/>Renal anomalies</td>
                    <td headers="hd_h_bor.T.major_and_minor_diagnostic_criteri_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">External auditory canal anomalies<break/>Middle ear anomalies<break/>Inner ear anomalies<break/>Preauricular tags<break/>Other: facial asymmetry, palate abnormalities</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <p>
              <bold>Second branchial arch anomalies</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Branchial cleft sinus tract appearing as a pin-point opening anterior to the sternocleidomastoid muscle, usually in the lower third of the neck</p>
              </list-item>
              <list-item>
                <p>Branchial cleft cyst appearing as a palpable mass under the sternocleidomastoid muscle, usually above the level of the hyoid bone</p>
              </list-item>
            </list>
            <p>
              <bold>Otologic findings</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Deafness: mild to profound in degree; conductive, sensorineural, or mixed in type (see <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object>)</p>
              </list-item>
              <list-item>
                <p>Preauricular pits</p>
              </list-item>
              <list-item>
                <p>Auricular malformation (lop ear, cupped ear)</p>
              </list-item>
              <list-item>
                <p>Preauricular tags</p>
              </list-item>
              <list-item>
                <p>Abnormalities of the external auditory canal: atresia or stenosis</p>
              </list-item>
              <list-item>
                <p>Middle ear abnormalities: malformation, malposition, dislocation, or fixation of the ossicles; reduction in size or malformation of the middle ear space</p>
              </list-item>
              <list-item>
                <p>Inner ear abnormalities: cochlear hypoplasia; enlargement of the cochlear and vestibular aqueducts; hypoplasia of the lateral semicircular canal [<xref ref-type="bibr" rid="bor.REF.ceruti.2002.200">Ceruti et al 2002</xref>, <xref ref-type="bibr" rid="bor.REF.kemperman.2002.1033">Kemperman et al 2002</xref>]</p>
              </list-item>
            </list>
            <p>
              <bold>Renal anomalies</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Renal agenesis, hypoplasia, dysplasia</p>
              </list-item>
              <list-item>
                <p>Uretero-pelvic junction (UPJ) obstruction</p>
              </list-item>
              <list-item>
                <p>Calyceal cyst/diverticulum</p>
              </list-item>
              <list-item>
                <p>Calyectasis, pelviectasis, hydronephrosis, and vesicoureteral reflux</p>
              </list-item>
            </list>
            <p>Note: Individuals with an affected family member need only one major criterion to make the diagnosis of BOR syndrome [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>].</p>
          </sec>
          <sec id="bor.Branchiootic_Syndrome_BOS">
            <title>Branchiootic Syndrome (BOS)</title>
            <p>In the absence of structural renal anomalies, the clinical diagnosis of BOS should be considered. BOS is characterized by the presence of hearing loss, cupped ear malformation, preauricular pits, and branchial fistulae and the absence of renal anomalies.</p>
          </sec>
        </sec>
        <sec id="bor.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of a branchiootorenal spectrum disorder <bold>is established</bold> in a proband with the clinical features listed above and/or identification of a heterozygous pathogenic variant in one of the genes listed in <xref ref-type="table" rid="bor.T.major_and_minor_diagnostic_criteri">Table 1</xref>.</p>
          <p>Molecular testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Serial single-gene testing</bold> can be considered if (1) mutation of a particular gene accounts for a large proportion of the disease <bold>or</bold> (2) clinical findings, laboratory findings, ancestry, and related factors indicate that mutation of a particular gene is most likely. Sequence analysis of the gene of interest is performed first, followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, <italic toggle="yes">SIX1</italic>, and other genes of interest (see <xref ref-type="sec" rid="bor.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and the sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of BOR/BOS. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="bor.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Branchiootorenal Spectrum Disorders (BOR/BOS)</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2">Proportion of BOR/BOS Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detected by Test Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3" id="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></th>
                  <th headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3" id="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">EYA1</italic>
                  </td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">40%&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">80%</td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">20%</td>
                </tr>
                <tr>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SIX5</italic>
                  </td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2.5%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">None reported</td>
                </tr>
                <tr>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SIX1</italic>
                  </td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2%&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100%</td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">None reported</td>
                </tr>
                <tr>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_1_3 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_1 hd_h_bor.T.summary_of_molecular_genetic_testi_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="bor.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="bor" object-id="bor.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="bor.TF.2.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="bor.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="bor.TF.2.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="bor.TF.2.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="bor.TF.2.5">
                <label>5. </label>
                <p><xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al [2004]</xref>, <xref ref-type="bibr" rid="bor.REF.krug.2011.183">Krug et al [2011]</xref></p>
              </fn>
              <fn id="bor.TF.2.6">
                <label>6. </label>
                <p>Heterozygous pathogenic variants were identified in 5/95 (5.2%) unrelated individuals with BOR syndrome in whom an <italic toggle="yes">EYA1</italic> or <italic toggle="yes">SIX1</italic> pathogenic variant was not identified [<xref ref-type="bibr" rid="bor.REF.hoskins.2007.800">Hoskins et al 2007</xref>]; these data imply a <italic toggle="yes">SIX5</italic> mutation rate of fewer than 2.5% of persons with BOR syndrome.</p>
              </fn>
              <fn id="bor.TF.2.7">
                <label>7. </label>
                <p>Heterozygous pathogenic variants were identified in 10/247 (4.0%) unrelated individuals with BOR syndrome in whom an <italic toggle="yes">EYA1</italic> or <italic toggle="yes">SIX5</italic> pathogenic variant was not identified [<xref ref-type="bibr" rid="bor.REF.kochhar.2008.565">Kochhar et al 2008</xref>]. This prevalence implies that <italic toggle="yes">SIX1</italic> pathogenic variants account for approximately 2% of cases of BOR syndrome.</p>
              </fn>
              <fn id="bor.TF.2.8">
                <label>8. </label>
                <p>
                  <xref ref-type="bibr" rid="bor.REF.brophy.2013.1339">Brophy et al [2013]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="bor.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="bor.Clinical_Description">
          <title>Clinical Description</title>
          <p>Branchiootorenal spectrum disorders include branchiootorenal (BOR) syndrome and branchiootic syndrome (BOS).</p>
          <sec id="bor.BOR_Syndrome">
            <title>BOR Syndrome</title>
            <p>The presence, severity, and type of branchial arch, otologic, audiologic, and renal abnormality in BOR syndrome may differ from right side to left side in an affected individual and among individuals in the same family.</p>
            <p><bold>Second branchial arch anomalies</bold> include branchial cleft cyst or sinus tract (cervical fistulae) (50%). Cysts can become infected and sinus tracts can drain.</p>
            <p><bold>Otologic findings,</bold> found in more than 90% of individuals with BOR syndrome [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>], include:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Hearing loss</bold> (&#x0003e;90%) [<xref ref-type="bibr" rid="bor.REF.stinckens.2001.163">Stinckens et al 2001</xref>]</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Type: mixed (52%), conductive (33%), sensorineural (29%)</p>
                  </list-item>
                  <list-item>
                    <p>Severity: mild (27%), moderate (22%), severe (33%), profound (16%)</p>
                  </list-item>
                  <list-item>
                    <p>Non-progressive (~70%), progressive (~30%, correlates with presence of a dilated vestibular aqueduct on computed tomography) [<xref ref-type="bibr" rid="bor.REF.kemperman.2004.523">Kemperman et al 2004</xref>]</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>
                  <bold>Abnormalities of the pinnae</bold>
                </p>
                <list list-type="bullet">
                  <list-item>
                    <p>Preauricular pits (82%)</p>
                  </list-item>
                  <list-item>
                    <p>Lop ear malformation (36%)</p>
                  </list-item>
                  <list-item>
                    <p>Preauricular tags (13%)</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p><bold>Abnormalities of the external auditory canal.</bold> Atresia or stenosis (29%)</p>
              </list-item>
              <list-item>
                <p><bold>Middle ear abnormalities.</bold> Malformation, malposition, dislocation, or fixation of the ossicles; reduction in size or malformation of the middle ear space</p>
              </list-item>
              <list-item>
                <p><bold>Inner ear abnormalities.</bold> Variably present:</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Cochlear hypoplasia</p>
                  </list-item>
                  <list-item>
                    <p>Enlargement of the cochlear and vestibular aqueducts</p>
                  </list-item>
                  <list-item>
                    <p>Hypoplasia of the lateral semicircular canal [<xref ref-type="bibr" rid="bor.REF.ceruti.2002.200">Ceruti et al 2002</xref>, <xref ref-type="bibr" rid="bor.REF.kemperman.2002.1033">Kemperman et al 2002</xref>]</p>
                  </list-item>
                </list>
              </list-item>
            </list>
            <p><bold>Renal anomalies.</bold> Renal malformations can be unilateral or bilateral and can occur in any combination. The most severe malformations result in pregnancy loss (since bilateral renal agenesis can end in miscarriage) or neonatal death; ESRD later in life may necessitate dialysis or transplantation.</p>
            <p>Although renal anomalies are common, the true prevalence is difficult to establish because not all affected individuals undergo intravenous pyelography or renal ultrasonography. In a study in which 21 affected individuals had one of these two tests, renal anomalies were noted in 67% [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>] and included the following:</p>
            <list list-type="bullet">
              <list-item>
                <p>Renal agenesis (29%), hypoplasia (19%), dysplasia (14%)</p>
              </list-item>
              <list-item>
                <p>Uretero-pelvic junction (UPJ) obstruction (10%)</p>
              </list-item>
              <list-item>
                <p>Calyceal cyst/diverticulum (10%)</p>
              </list-item>
              <list-item>
                <p>Calyectasis, pelviectasis, hydronephrosis, and vesicoureteral reflux (5% each)</p>
              </list-item>
            </list>
            <p><bold>Other findings</bold> [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>]</p>
            <list list-type="bullet">
              <list-item>
                <p>Lacrimal duct aplasia</p>
              </list-item>
              <list-item>
                <p>Short or cleft palate</p>
              </list-item>
              <list-item>
                <p>Retrognathia</p>
              </list-item>
              <list-item>
                <p>Euthyroid goiter</p>
              </list-item>
              <list-item>
                <p>Facial nerve paralysis</p>
              </list-item>
              <list-item>
                <p>Gustatory lacrimation</p>
              </list-item>
            </list>
          </sec>
          <sec id="bor.Branchiootic_Syndrome_BOS_1">
            <title>Branchiootic Syndrome (BOS)</title>
            <p>BOS can be caused by pathogenic variants of <italic toggle="yes">EYA1</italic>, and is characterized by deafness, cupped ear malformation, preauricular pits, and branchial fistulae, in the <bold>absence</bold> of renal anomalies. In two families with BOS and pathogenic variants in <italic toggle="yes">EYA1</italic>, affected individuals had sensorineural (25%), mixed (66%), or conductive (9%) hearing loss; branchial fistulae (100%); preauricular pits (80%); and cupped ear malformation (60%) [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>].</p>
          </sec>
        </sec>
        <sec id="bor.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>A genotype-phenotype correlation has not been defined for BOR/BOS. To compare phenotype with genotype, <xref ref-type="bibr" rid="bor.REF.zhang.2004.295">Zhang et al [2004]</xref> grouped <italic toggle="yes">EYA1</italic> pathogenic variants as inactivating (i.e., splice site variants, insertions, nonsense variants, and duplications and deletions of &#x0003e;3 bp) or non-inactivating (i.e., pathogenic missense variants and 3-bp deletions). Using this criterion, they showed that <italic toggle="yes">EYA1</italic> inactivating variants are not associated with a more severe phenotype (p=0.799).</p>
          <p>Mice with a targeted deletion of the ortholog <italic toggle="yes">Six1</italic> display a wide range of phenotypes. When the mutant Six1 protein is not expressed, the presence of a phenotype depends on the genetic background [<xref ref-type="bibr" rid="bor.REF.xu.2003.3085">Xu et al 2003</xref>]. For example, murine deletions in <italic toggle="yes">Six1</italic> modify the severity of the phenotype caused by deletions in the ortholog <italic toggle="yes">Eya1</italic> [<xref ref-type="bibr" rid="bor.REF.li.2003.247">Li et al 2003</xref>, <xref ref-type="bibr" rid="bor.REF.xu.2003.3085">Xu et al 2003</xref>, <xref ref-type="bibr" rid="bor.REF.zheng.2003.3989">Zheng et al 2003</xref>]. This type of double heterozygosity has not been described in persons with a BOR/BOS phenotype. However, of families reported with <italic toggle="yes">SIX1</italic> pathogenic variants, only two have renal abnormalities, suggesting that genetic background significantly affects the severity of renal defects in BOR syndrome.</p>
          <p>Other explanations for the range of phenotypes include haploinsufficiency and dominant-negative or gain-of-function effects. Of these possibilities, when considering <italic toggle="yes">SIX1</italic> and <italic toggle="yes">SIX5</italic> pathogenic variants, complex dominant-negative and/or gain-of-function mechanisms are appealing, as no inactivating variants (i.e., splice site variants, insertions, nonsense variants, and duplications and deletions of &#x0003e;3 bp) have been reported in families with branchiootorenal spectrum disorders and pathogenic variants in <italic toggle="yes">SIX1</italic> or <italic toggle="yes">SIX5</italic> [<xref ref-type="bibr" rid="bor.REF.hoskins.2007.800">Hoskins et al 2007</xref>, <xref ref-type="bibr" rid="bor.REF.kochhar.2008.565">Kochhar et al 2008</xref>].</p>
          <p>A parent-of-origin effect does not appear to be present: renal defects have been reported in six live-born offspring of affected fathers and four live-born offspring of affected mothers.</p>
        </sec>
        <sec id="bor.Penetrance">
          <title>Penetrance</title>
          <p>Based on careful clinical studies of large pedigrees, branchiootorenal spectrum disorders appear to have 100% penetrance, although expressivity is highly variable [<xref ref-type="bibr" rid="bor.REF.chang.2004.582">Chang et al 2004</xref>].</p>
        </sec>
        <sec id="bor.Nomenclature">
          <title>Nomenclature</title>
          <p>BOR syndrome is known eponymously as Melnick-Fraser syndrome. While phenotypic descriptions are applied to BOR, BOS, and even branchiootoureteral (BOU) syndrome, these clinical distinctions must be considered in light of the associated molecular genetics. Many affected persons in families segregating <italic toggle="yes">EYA1</italic> pathogenic variants have clinical findings consistent with the diagnosis of BOR; however, some affected persons in these same families have clinical findings consistent with BOS or BOU [<xref ref-type="bibr" rid="bor.REF.orten.2008.537">Orten et al 2008</xref>]. For this reason, these syndromes are best considered as branchiootorenal spectrum disorders.</p>
        </sec>
        <sec id="bor.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of branchiootorenal spectrum disorders is not known. In 1976, GR Fraser surveyed 3,640 children with profound hearing impairment and found only five (0.15%) with a family history of branchial fistulae and preauricular pits (1:700,000) [<xref ref-type="bibr" rid="bor.REF.fraser.1976">Fraser 1976</xref>]. Four years later, in a study by FC Fraser of 421 children in the Montreal School for the Deaf, 2% of the profoundly deaf students had BOR syndrome [<xref ref-type="bibr" rid="bor.REF.fraser.1980.341">Fraser et al 1980</xref>]. Using these data, <xref ref-type="bibr" rid="bor.REF.fraser.1980.341">Fraser et al [1980]</xref> estimated the prevalence of BOR syndrome at 1:40,000. The true prevalence is probably somewhere between these extremes.</p>
        </sec>
      </sec>
      <sec id="bor.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">EYA1.</italic></bold> Otofaciocervical (OFC) syndrome. Two individuals with <italic toggle="yes">de novo</italic> deletions of <italic toggle="yes">EYA1</italic> and surrounding region had complex phenotypes including features of BOR syndrome [<xref ref-type="bibr" rid="bor.REF.rickard.2001.398">Rickard et al 2001</xref>].</p>
        <p><bold><italic toggle="yes">SIX5</italic>.</bold> No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">SIX5</italic>.</p>
        <p><bold><italic toggle="yes">SIX1</italic>.</bold>
<italic toggle="yes">SIX1</italic> was considered a candidate gene for DFNA23, as the DFNA23 locus maps to chromosome 14q21-q22. However, in a family purported to have DFNA23, although a pathogenic variant was found in <italic toggle="yes">SIX1</italic>, the individual in question also had a solitary left hypodysplastic kidney with vesicoureteral reflux and progressive renal failure consistent with the diagnosis of a branchiootorenal spectrum disorder.</p>
      </sec>
      <sec id="bor.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>More than 400 genetic syndromes that include hearing loss have been described [<xref ref-type="bibr" rid="bor.REF.toriello.2004">Toriello et al 2004</xref>]. Although the branchiootorenal spectrum disorders have a distinctive phenotype that is readily appreciated when segregating in large families, the diagnosis can be more difficult to establish in small families. See <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object>.</p>
      </sec>
      <sec id="bor.Management">
        <title>Management</title>
        <sec id="bor.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with a branchiootorenal spectrum disorder (BOR/BOS), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Second branchial arch anomalies.</bold> Cervical examination for fistulae; computed tomography of the neck if a mass is palpable under the sternocleidomastoid muscle above the level of the hyoid bone</p>
            </list-item>
            <list-item>
              <p>
                <bold>Otologic findings</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>A complete assessment of auditory acuity using ABR, emission testing, and pure tone audiometry (see <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object>)</p>
                </list-item>
                <list-item>
                  <p>Computed tomography of the temporal bones, especially if the hearing impairment fluctuates or is progressive</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Renal anomalies.</bold> Renal ultrasound examination and/or excretory urography (intravenous pyelography); tests of renal function: BUN and creatinine; urinanalysis</p>
            </list-item>
            <list-item>
              <p><bold>Other.</bold> Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="bor.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Recommended treatment:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Second branchial arch anomalies.</bold> Excise branchial cleft cysts/fistulae.</p>
            </list-item>
            <list-item>
              <p>
                <bold>Otologic anomalies</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Fit with appropriate aural habilitation as indicated.</p>
                </list-item>
                <list-item>
                  <p>Enroll in an appropriate educational program for the hearing impaired.</p>
                </list-item>
                <list-item>
                  <p>Consider canaloplasty to correct an atretic canal; however, in individuals with BOR/BOS, associated middle ear anomalies (e.g., a facial nerve overriding the oval window) can preclude a successful result. Evaluate the status of the middle ear preoperatively by obtaining thin-cut CT images of the temporal bones in both the axial and coronal planes.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Renal anomalies</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Treat urologic and renal abnormalities in the standard manner.</p>
                </list-item>
                <list-item>
                  <p>If renal anomalies (e.g., vesicoureteral reflux) are present, medical and surgical treatment may prevent progression to end-stage renal disease (ESRD).</p>
                </list-item>
                <list-item>
                  <p>If ESRD develops, consider renal transplantation.</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="bor.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Otologic manifestations of disease can often be surgically corrected with correction of the cupped-ear malformation and occasionally improvement in the conductive component of the hearing loss.</p>
          <p>Branchial arch anomalies can be surgically corrected.</p>
        </sec>
        <sec id="bor.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Renal anomalies such as vesicoureteral reflux can lead to progressive renal failure, a secondary complication that can be avoided by surgical correction of retrograde flow of urine from the bladder into the ureter.</p>
        </sec>
        <sec id="bor.Surveillance">
          <title>Surveillance</title>
          <p>Surveillance for otologic and renal anomalies should be offered as described below.</p>
          <p><bold>Otologic anomalies.</bold> Serial audiometry to survey for progression of hearing loss:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual examination by a physician who is familiar with hereditary hearing impairment</p>
            </list-item>
            <list-item>
              <p>Semiannual examination for hearing impairment and annual audiometry to assess stability of hearing loss (more frequent if fluctuation or progression is described by the affected individual)</p>
            </list-item>
          </list>
          <p>
            <bold>Renal anomalies</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Regular assessment of renal function to prevent progression to ESRD</p>
            </list-item>
            <list-item>
              <p>Semiannual/annual examination by a nephrologist and/or urologist if indicated, based on level of renal function and type of renal and/or collecting system malformation</p>
            </list-item>
          </list>
        </sec>
        <sec id="bor.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Individuals with renal abnormalities should use appropriate caution when taking medications (i.e., antibiotics and analgesics) that can impair renal function or require normal renal physiology for clearance.</p>
        </sec>
        <sec id="bor.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic relatives at risk for BOR/BOS to determine if a treatable and/or possibly progressive otologic and/or renal abnormality is present.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variant in the family is known;</p>
            </list-item>
            <list-item>
              <p>Comprehensive physical examination (to include hearing evaluation and renal imaging and function studies) if the pathogenic variant in the family is not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="bor.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="bor.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="bor.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="bor.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>The branchiootorenal spectrum disorders are inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="bor.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 90% of individuals diagnosed with a branchiootorenal spectrum disorder have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with a branchiootorenal spectrum disorder may have the disorder as the result of a <italic toggle="yes">de novo</italic>
<italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, or <italic toggle="yes">SIX1</italic> pathogenic variant. Approximately 10% of cases are caused by <italic toggle="yes">de novo</italic> pathogenic variants.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, two possible explanations are a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent (although no instances of germline mosaicism have been reported, it remains a possibility).</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include molecular genetic testing for the pathogenic variant identified in the proband and examination of the parents for hearing loss, preauricular pits, lacrimal duct stenosis, branchial fistulae and/or cysts, and renal anomalies. An apparently negative family history cannot be confirmed until appropriate evaluation of the parents has been performed.</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with a branchiootorenal spectrum disorder have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of a proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is diagnosed with a branchiootorenal spectrum disorder, the risk to each sib is 50%.</p>
            </list-item>
            <list-item>
              <p>Disease severity cannot be accurately predicted and is extremely variable even within the same family.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, or <italic toggle="yes">SIX1</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Each child of an individual with a branchiootorenal spectrum disorder has a 50% chance of inheriting the <italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, or <italic toggle="yes">SIX1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Disease severity cannot be accurately predicted and is extremely variable even within the same family.</p>
            </list-item>
          </list>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members may be at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="bor.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="bor.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a <italic toggle="yes">de novo</italic> pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="bor.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p><bold>Molecular genetic testing.</bold> If the <italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, or <italic toggle="yes">SIX1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of the gene of interest or custom prenatal testing.</p>
          <p><bold>Fetal ultrasound examination.</bold> For fetuses at increased risk for BOR syndrome, prenatal ultrasound examination at 16-17 weeks' gestation should be considered for evaluation of significant renal malformations and/or oligohydramnios.</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p>While requests for prenatal testing for significant medical conditions such as bilateral renal agenesis are generally accepted, requests for prenatal testing for conditions such as BOR syndrome may be more problematic. Variable expressivity makes it impossible to accurately predict which manifestations of BOR syndrome may occur and how mild or severe they will be. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">EYA1</italic>, <italic toggle="yes">SIX5</italic>, or <italic toggle="yes">SIX1</italic> pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="bor.Resources">
        <title>Resources</title>
      </sec>
      <sec id="bor.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="bor.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The vertebrate Eya gene family comprises four transcriptional activators that interact with other proteins in a conserved regulatory hierarchy to ensure normal embryologic development. The structure of these proteins includes a highly conserved 271-amino acid carboxy terminus called the eya-homologous region (eyaHR) and a more divergent proline-serine-threonine (PST)-rich (34%-41%) transactivation domain at the amino terminus (eya variable region, eyaVR) [<xref ref-type="bibr" rid="bor.REF.zhang.2004.295">Zhang et al 2004</xref>].</p>
          <p>Studies in <italic toggle="yes">Drosophila</italic> indicate that the eyaHR mediates interactions with the gene products of <italic toggle="yes">so</italic> (sine oculis) and <italic toggle="yes">dac</italic> (dachshund), and that expression of both <italic toggle="yes">eya</italic> and <italic toggle="yes">so</italic> is initiated by <italic toggle="yes">ey</italic> (eyeless). The vertebrate orthologs of <italic toggle="yes">so</italic> are members of the Six gene family and similarly bind with Eya proteins, inducing nuclear translocation of the resultant protein complex. Amino terminal transcriptional activation has been demonstrated for the <italic toggle="yes">Drosophila eya</italic> and murine <italic toggle="yes">Eya1, Eya2, Eya3</italic> gene products, an additional indication that <italic toggle="yes">Eya</italic> interactions and pathways are conserved across species.</p>
          <p>Expression of <italic toggle="yes">Eya</italic> genes is present in a wide variety of tissues early in embryogenesis, and although each gene has a unique expression pattern, extensive overlap exists. For example, murine studies have shown that <italic toggle="yes">Eya1</italic>, <italic toggle="yes">Eya2</italic>, and <italic toggle="yes">Eya4</italic> are all expressed in the presomitic mesoderm and head mesenchyme, but only <italic toggle="yes">Eya1</italic> and <italic toggle="yes">Eya4</italic> are expressed in the otic vesicle [<xref ref-type="bibr" rid="bor.REF.wayne.2001.195">Wayne et al 2001</xref>]. <italic toggle="yes">Eya3</italic> expression is restricted to craniofacial and branchial arch mesenchyme in regions underlying or surrounding the cranial placodes expressing the gene product of <italic toggle="yes">Eya1</italic>, <italic toggle="yes">Eya2</italic>, or <italic toggle="yes">Eya4</italic>.</p>
          <p><italic toggle="yes">Six1</italic> functions as both a transactivator and a transcriptional repressor, depending on its cofactors [<xref ref-type="bibr" rid="bor.REF.silver.2003.5989">Silver et al 2003</xref>, <xref ref-type="bibr" rid="bor.REF.bricaud.2006.10438">Bricaud &#x00026; Collazo 2006</xref>].</p>
          <sec id="bor.EYA1">
            <title>
              <italic toggle="yes">EYA1</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">EYA1</italic> consists of 16 coding exons that extend over 156 kb. It has at least four alternatively spliced transcripts. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bor" object-id="bor.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p>The 5' exons (exon -1 and the 3' end of exon 1) produce an open reading frame (ORF) that could add more than 156 amino acids to the amino terminal of <italic toggle="yes">EYA1</italic>; however, it is not known whether this sequence is translated. The seventeen introns of <italic toggle="yes">EYA1</italic> vary in size from 0.1 to 27.5 kb [<xref ref-type="bibr" rid="bor.REF.orten.2008.537">Orten et al 2008</xref>].</p>
            <p><bold>Benign variants.</bold> Numerous sequence variants of <italic toggle="yes">EYA1</italic> have been reported. When allelic variants are discovered, it is not always clear whether they are disease causing. Since pathogenic variants in <italic toggle="yes">EYA1</italic> are <bold>not</bold> found in 60% of people with BOR/BOS, caution must be used when interpreting the effect of pathogenic missense variants in a single family, especially if rigorous population-based studies have not been performed.</p>
            <p><bold>Pathogenic variants.</bold> More than 80 different pathogenic variants of <italic toggle="yes">EYA1</italic> that result in BOR/BOS have been identified [<xref ref-type="bibr" rid="bor.REF.kumar.1998.443">Kumar et al 1998</xref>]. These include nonsense [<xref ref-type="bibr" rid="bor.REF.kumar.1998.443">Kumar et al 1998</xref>], missense, frameshift [<xref ref-type="bibr" rid="bor.REF.kumar.1998.443">Kumar et al 1998</xref>], and splice site variants and gross deletions and insertions. A gross deletion of ~2.7 Mbp appears to be a relatively common cause of BOR/BOS in affected persons who are negative for <italic toggle="yes">EYA1</italic> coding region and splice site pathogenic variants. The breakpoints of this deletion reside in long terminal repeat elements of the ERV1 retrovirus family [<xref ref-type="bibr" rid="bor.REF.sanchezvalle.2010.2854">Sanchez-Valle et al 2010</xref>, <xref ref-type="bibr" rid="bor.REF.brophy.2013.1339">Brophy et al 2013</xref>].</p>
            <p>All of these pathogenic variants affect at least two <italic toggle="yes">EYA1</italic> isoforms. In addition, the presence of pathogenic variants in exon 12 (which is skipped in the shortest transcript EYA1D, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_172059.3">NM_172059.3</ext-link>) indicates that the longer isoforms are necessary for EYA1 function [<xref ref-type="bibr" rid="bor.REF.orten.2008.537">Orten et al 2008</xref>].</p>
            <p><bold>Normal gene product.</bold> The proteins encoded by the transcript variants EYA1A (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_742057.1">NP_742057.1</ext-link>; 559 amino acids) and EYA1B (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_742055.1">NP_742055.1</ext-link>; 592 amino acids) differ only in their N-terminal region. EYA1C (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000503.5">NM_000503.5</ext-link>) has two overlapping open reading frames (ORFs). One of the predicted ORFs is identical to that of EYA1B; however, for this ORF, the first stop codon is an additional 369 nucleotides upstream. The full extent of the second ORF has not been completely determined; EYA1C could give rise to two distinct proteins or alternatively the two ORFs could be translated into a single protein by ribosomal frame shifting.</p>
            <p>The 5' UTR variations and alternate splicing are consistent with multifaceted control of <italic toggle="yes">EYA1</italic> gene expression, which is particularly relevant because the protein encodes products important for inner-ear, kidney, and branchial-arch development.</p>
            <p>Eya proteins have intrinsic phosphatase activity, enabling it to serve as a promoter-specific transcriptional co-activator. It is part of the Six-Eya-Dach regulatory network that defines a molecular mechanism by which a recruited co-activator with phosphatase function (Eya) derepresses target genes. Six1 acts as a repressor or as an activator of gene transcription based, at least in part, on the recruitment of opposing cofactors. The recruitment of Dach is associated with co-repressor activity, while the recruitment of Eya is associated with co-activator activity. The co-activator activity of Eya is based on its phosphatase activity, which reverses the co-repressor activity of Dach and permits the recruitment of other co-activators, including CREB-binding protein (CBP) [<xref ref-type="bibr" rid="bor.REF.li.2003.247">Li et al 2003</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Some pathogenic variants in <italic toggle="yes">EYA1</italic> generate mutated proteins that are rapidly degraded, implying that haploinsufficiency can cause BOR/BOS [<xref ref-type="bibr" rid="bor.REF.zhang.2004.295">Zhang et al 2004</xref>]. These data are also consistent with the presence of large deletions of one allele of <italic toggle="yes">EYA1</italic> in some families with BOR/BOS. Based on data derived from in vivo studies of the <italic toggle="yes">Drosophila</italic> developmental system, other pathogenic missense variants affect either phosphatase or transcription function [<xref ref-type="bibr" rid="bor.REF.mutsuddi.2005.687">Mutsuddi et al 2005</xref>]. These different types of mutational effects are predicted to lead to differences in phenotype.</p>
          </sec>
          <sec id="bor.SIX1">
            <title>
              <italic toggle="yes">SIX1</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SIX1</italic> has a transcript of 1376 bp and two exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bor" object-id="bor.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Eight <italic toggle="yes">SIX1</italic> pathogenic variants have been reported [<xref ref-type="bibr" rid="bor.REF.ruf.2004.8090">Ruf et al 2004</xref>, <xref ref-type="bibr" rid="bor.REF.ito.2006.796">Ito et al 2006</xref>, <xref ref-type="bibr" rid="bor.REF.kochhar.2008.565">Kochhar et al 2008</xref>]. One of these, c.328C&#x0003e;T, was detected in six unrelated families from multiple ethnic groups [<xref ref-type="bibr" rid="bor.REF.kochhar.2008.565">Kochhar et al 2008</xref>].</p>
            <table-wrap id="bor.T.six1_pathogenic_variants_discussed" orientation="portrait" position="anchor">
              <label>Table 3. </label>
              <caption>
                <p><italic toggle="yes">SIX1</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                    <th id="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.50T&#x0003e;A</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val17Glu</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_3" rowspan="6" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_005982">NM_005982.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_005973.1">NP_005973.1</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.317T&#x0003e;G</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Val106Gly</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.328C&#x0003e;T</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg110Trp</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.334C&#x0003e;T</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg112Cys</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.386A&#x0003e;G</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr129Cys</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.397_399delGAG</td>
                    <td headers="hd_h_bor.T.six1_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu133del</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">SIX1</italic> is one of six members of the <italic toggle="yes">SIX</italic> gene family <italic toggle="yes">(SIX1-SIX6</italic>) in humans. Like each of the transcribed proteins in this family, homeobox protein SIX1 has both a conserved SIX domain and homeodomain, which are required for DNA binding. Expression of SIX1 is necessary for normal development of the inner ear, nose, thymus, kidney, and skeletal muscle. Mice with a targeted deletion of the ortholog <italic toggle="yes">Six1</italic> have been shown to have abnormalities of these organs [<xref ref-type="bibr" rid="bor.REF.ando.2005.3026">Ando et al 2005</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Functional characterization of several <italic toggle="yes">SIX1</italic> pathogenic variants has shown that they appear to have ONE of the FOLLOWING consequences [<xref ref-type="bibr" rid="bor.REF.ohto.1999.6815">Ohto et al 1999</xref>, <xref ref-type="bibr" rid="bor.REF.ruf.2004.8090">Ruf et al 2004</xref>, <xref ref-type="bibr" rid="bor.REF.patrick.2009.20781">Patrick et al 2009</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p>Abolish SIX1-EYA1 complex formation, thus preventing nuclear localization (i.e., p.Val17Glu) OR</p>
              </list-item>
              <list-item>
                <p>Abrogate DNA binding of the SIX1-EYA1 complex (i.e., p.Val106Gly, p.Arg110Trp, p.Arg112Cys, p.Tyr129Cys, p.Glu133del)</p>
              </list-item>
            </list>
            <p>The fact that no inactivating variants have been discovered suggests that the BOR/BOS phenotype is not the result of haploinsufficiency [<xref ref-type="bibr" rid="bor.REF.ruf.2004.8090">Ruf et al 2004</xref>].</p>
          </sec>
          <sec id="bor.SIX5">
            <title>
              <italic toggle="yes">SIX5</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SIX5</italic> has a transcript of 3145 bp and three exons. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="bor" object-id="bor.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Based on the identification of pathogenic variants in <italic toggle="yes">SIX5</italic> in five of 95 unrelated individuals with BOR/BOS syndrome, at least four pathogenic variants are known [<xref ref-type="bibr" rid="bor.REF.hoskins.2007.800">Hoskins et al 2007</xref>] (see <xref ref-type="table" rid="bor.T.six5_pathogenic_variants_discussed">Table 4</xref>).</p>
            <table-wrap id="bor.T.six5_pathogenic_variants_discussed" orientation="portrait" position="anchor">
              <label>Table 4. </label>
              <caption>
                <p><italic toggle="yes">SIX5</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                    <th id="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                    <th id="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.472G&#x0003e;A</td>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala158Thr</td>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_3" rowspan="4" valign="middle" align="left" colspan="1">
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_175875.3">NM_175875.3</ext-link>
                      <break/>
                      <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_787071.2">NP_787071.2</ext-link>
                    </td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.886G&#x0003e;A</td>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala296Thr</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1093G&#x0003e;A</td>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly365Arg</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1655C&#x0003e;T</td>
                    <td headers="hd_h_bor.T.six5_pathogenic_variants_discussed_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr552Met</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
                </fn>
                <fn>
                  <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Normal gene product.</bold> The homeobox protein SIX5 has 739 amino acid residues and a high degree of homology to SIX1, and is known to interact directly with EYA1. However, unlike SIX1, SIX5 has an additional activation domain (AD) at the C-terminus [<xref ref-type="bibr" rid="bor.REF.hoskins.2007.800">Hoskins et al 2007</xref>].</p>
            <p><bold>Abnormal gene product.</bold> In vitro data suggest that both p.Ala158Thr and p.Thr552Met residues of SIX5 may be required for efficient binding with EYA1 [<xref ref-type="bibr" rid="bor.REF.hoskins.2007.800">Hoskins et al 2007</xref>]. Yeast two-hybrid liquid &#x003b2;-galactosidase assays using GAL4 BD-SIX5 and GAL4 AD-Eya1D constructs cause strong <italic toggle="yes">lacZ</italic> expression as a result of interaction between the two fusion proteins. The p.Ala296Thr and p.Gly365Arg pathogenic variants result in a slight reduction in <italic toggle="yes">lacZ</italic> expression, while both p.Ala158Thr and p.Thr552Met show more than a twofold reduction in <italic toggle="yes">lacZ</italic> expression.</p>
          </sec>
        </sec>
      </sec>
      <sec id="bor.References">
        <title>References</title>
        <sec id="bor.Published_GuidelinesConsensus_Statem">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="bor.Published_GuidelinesConsensus_Statem.reflist0">
            <ref id="bor.REF1">
              <mixed-citation publication-type="web">American College of Medical Genetics. Genetics evaluation guidelines for the etiologic diagnosis of congenital hearing loss. Genetic evaluation of congenital hearing loss expert panel. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110944/">online</ext-link>. 2002. Accessed 2-8-17.</mixed-citation>
            </ref>
            <ref id="bor.REF2">
              <mixed-citation publication-type="web">American College of Medical Genetics. Statement on universal newborn hearing screening. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/StaticPages/Universal_Hearing.pdf">online</ext-link>. 2000. Accessed 2-8-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="bor.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="bor.Literature_Cited.reflist0">
            <ref id="bor.REF.ando.2005.3026">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ando</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawakami</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Slc12a2 is a direct target of two closely related homeobox proteins, Six1 and Six4.</article-title>
                <source>FEBS J</source>
                <volume>272</volume>
                <fpage>3026</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">15955062</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.bricaud.2006.10438">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bricaud</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collazo</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The transcription factor six1 inhibits neuronal and promotes hair cell fate in the developing zebrafish (Danio rerio) inner ear.</article-title>
                <source>J Neurosci</source>
                <volume>26</volume>
                <fpage>10438</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17035528</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.brophy.2013.1339">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brophy</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alasti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Darbro</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manak</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Genome-wide copy number variation analysis of a Branchio-Oto-Renal syndrome cohort identifies a recombination hotspot and implicates new candidate genes.</article-title>
                <source>Hum Genet.</source>
                <year>2013</year>
                <volume>132</volume>
                <fpage>1339</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">23851940</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.ceruti.2002.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ceruti</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stinckens</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casselman</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Temporal bone anomalies in the branchio-oto-renal syndrome: detailed computed tomographic and magnetic resonance imaging findings.</article-title>
                <source>Otol Neurotol</source>
                <volume>23</volume>
                <fpage>200</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">11875350</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.chang.2004.582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menezes</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meyer</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cucci</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vervoort</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Branchio-oto-renal syndrome: the mutation spectrum in EYA1 and its phenotypic consequences.</article-title>
                <source>Hum Mutat</source>
                <volume>23</volume>
                <fpage>582</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15146463</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.fraser.1980.341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fraser</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sproule</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halal</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>1980</year>
                <article-title>Frequency of the branchio-oto-renal (BOR) syndrome in children with profound hearing loss.</article-title>
                <source>Am J Med Genet</source>
                <volume>7</volume>
                <fpage>341</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7468659</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.fraser.1976">
              <mixed-citation publication-type="book">Fraser GR. <italic toggle="yes">The Causes of Profound Deafness in Childhood</italic>. Baltimore, MD: Johns Hopkins University Press; 1976.</mixed-citation>
            </ref>
            <ref id="bor.REF.hoskins.2007.800">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hoskins</surname>
                    <given-names>BE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cramer</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvius</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zou</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orten</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weil</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petit</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>PX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrandt</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Transcription factor SIX5 is mutated in patients with branchio-oto-renal syndrome.</article-title>
                <source>Am J Hum Genet</source>
                <volume>80</volume>
                <fpage>800</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17357085</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.ito.2006.796">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noguchi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yashima</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitamura</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>SIX1 mutation associated with enlargement of the vestibular aqueduct in a patient with branchio-oto syndrome.</article-title>
                <source>Laryngoscope</source>
                <volume>116</volume>
                <fpage>796</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16652090</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.kemperman.2002.1033">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kemperman</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosten</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huygen</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Inner ear anomalies are frequent but nonobligatory features of the branchio-oto-renal syndrome.</article-title>
                <source>Arch Otolaryngol Head Neck Surg</source>
                <volume>128</volume>
                <fpage>1033</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12220207</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.kemperman.2004.523">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kemperman</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huygen</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joosten</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Evidence of progression and fluctuation of hearing impairment in branchio-oto-renal syndrome.</article-title>
                <source>Int J Audiol</source>
                <volume>43</volume>
                <fpage>523</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">15726843</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.kochhar.2008.565">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kochhar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orten</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorensen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CWRJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJH</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>SIX1 mutation screening in 247 branchio-oto-renal syndrome families: a recurrent missense mutation associated with BOR.</article-title>
                <source>Hum Mut</source>
                <volume>29</volume>
                <fpage>565</fpage>
                <pub-id pub-id-type="pmid">18330911</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.krug.2011.183">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Krug</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moriniere</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koubi</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabriel</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antignac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heidet</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Mutation screening of the EYA1, SIX1, and SIX5 genes in a large cohort of patients harboring Branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations.</article-title>
                <source>Hum Mutat</source>
                <volume>32</volume>
                <fpage>183</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">21280147</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.kumar.1998.443">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weston</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marres</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Identification of three novel mutations in human EYA1 protein associated with branchio-oto-renal syndrome.</article-title>
                <source>Hum Mutat</source>
                <volume>11</volume>
                <fpage>443</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9603436</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.li.2003.247">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oghi</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krones</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bush</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Glass</surname>
                    <given-names>CK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nigam</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aggarwal</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maas</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rose</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenfeld</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis.</article-title>
                <source>Nature</source>
                <volume>426</volume>
                <fpage>247</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">14628042</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.mutsuddi.2005.687">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mutsuddi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chaffee</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cassidy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silver</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tootle</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebay</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Using Drosophila to decipher how mutations associated with human branchio-oto-renal syndrome and optical defects compromise the protein tyrosine phosphatase and transcriptional functions of eyes absent.</article-title>
                <source>Genetics</source>
                <volume>170</volume>
                <fpage>687</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">15802522</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.ohto.1999.6815">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ohto</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamada</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tago</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tominaga</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozaki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sato</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawakami</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya.</article-title>
                <source>Mol Cell Biol.</source>
                <year>1999</year>
                <volume>19</volume>
                <fpage>6815</fpage>
                <lpage>24</lpage>
                <pub-id pub-id-type="pmid">10490620</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.orten.2008.537">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Orten</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischer</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorensen</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Radhakrishna</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marres</surname>
                    <given-names>HA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Camp</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Welch</surname>
                    <given-names>KO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimberling</surname>
                    <given-names>WJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Branchio-oto-renal syndrome (BOR): novel mutations in the EYA1 gene, and a review of the mutational genetics of BOR.</article-title>
                <source>Hum Mutat</source>
                <volume>29</volume>
                <fpage>537</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">18220287</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.patrick.2009.20781">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patrick</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schiemann</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yang</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ford</surname>
                    <given-names>HL</given-names>
                  </name>
                </person-group>
                <article-title>Biochemical and functional characterization of six SIX1 Branchio-oto-renal syndrome mutations.</article-title>
                <source>J Biol Chem.</source>
                <year>2009</year>
                <volume>284</volume>
                <fpage>20781</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">19497856</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.rickard.2001.398">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rickard</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parker</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van't Hoff</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnicoat</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell-Eggitt</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winter</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Oto-facio-cervical (OFC) syndrome is a contiguous gene deletion syndrome involving EYA1: molecular analysis confirms allelism with BOR syndrome and further narrows the Duane syndrome critical region to 1 cM.</article-title>
                <source>Hum Genet</source>
                <volume>108</volume>
                <fpage>398</fpage>
                <lpage>403</lpage>
                <pub-id pub-id-type="pmid">11409867</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.ruf.2004.8090">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ruf</surname>
                    <given-names>RG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>PX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvius</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Otto</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beekmann</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muerb</surname>
                    <given-names>UT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuhaus</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kemper</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>RM</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Brophy</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gattas</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruf</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stratakis</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weil</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petit</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hildebrandt</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes.</article-title>
                <source>Proc Natl Acad Sci U S A</source>
                <volume>101</volume>
                <fpage>8090</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15141091</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.sanchezvalle.2010.2854">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sanchez-Valle</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Potocki</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xia</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carlin</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michel</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabrera-Meza</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brundage</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eifert</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stankiewicz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheung</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lalani</surname>
                    <given-names>SR</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>HERV-Mediated Genomic Rearrangement of epsilon YA1 in an Individual With Branchio-oto-renal Syndrome.</article-title>
                <source>Am J Med Genet A</source>
                <volume>152A</volume>
                <fpage>2854</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">20979191</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.silver.2003.5989">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Silver</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davies</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Doyon</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rebay</surname>
                    <given-names>I</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Functional dissection of eyes absent reveals new modes of regulation within the retinal determination gene network.</article-title>
                <source>Mol Cell Biol</source>
                <volume>23</volume>
                <fpage>5989</fpage>
                <lpage>99</lpage>
                <pub-id pub-id-type="pmid">12917324</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.stinckens.2001.163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stinckens</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Standaert</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casselman</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huygen</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van de Wallen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cremers</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The presence of a widened vestibular aqueduct and progressive sensorineural hearing loss in the branchio-oto-renal syndrome. A family study.</article-title>
                <source>Int J Pediatr Otorhinolaryngol</source>
                <volume>59</volume>
                <fpage>163</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11397497</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.toriello.2004">
              <mixed-citation publication-type="book">Toriello HV, Reardon W, Gorlin RJ. <italic toggle="yes">Hereditary Hearing Loss and its Syndromes</italic>. Oxford University Press; 2004.</mixed-citation>
            </ref>
            <ref id="bor.REF.wayne.2001.195">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wayne</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robertson</surname>
                    <given-names>NG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeClau</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tranebjarg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Camp</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus.</article-title>
                <source>Hum Mol Genet</source>
                <volume>10</volume>
                <fpage>195</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">11159937</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.xu.2003.3085">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>PX</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maire</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laclef</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvius</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Six1 is required for the early organogenesis of mammalian kidney.</article-title>
                <source>Development</source>
                <volume>130</volume>
                <fpage>3085</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">12783782</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.zhang.2004.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knosp</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maconochie</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A comparative study of Eya1 and Eya4 protein function and its implication in branchio-oto-renal syndrome and DFNA10.</article-title>
                <source>J Assoc Res Otolaryngol</source>
                <volume>5</volume>
                <fpage>295</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">15492887</pub-id>
              </element-citation>
            </ref>
            <ref id="bor.REF.zheng.2003.3989">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zheng</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>ZB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvius</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>PX</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>The role of Six1 in mammalian auditory system development.</article-title>
                <source>Development</source>
                <volume>130</volume>
                <fpage>3989</fpage>
                <lpage>4000</lpage>
                <pub-id pub-id-type="pmid">12874121</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="bor.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="bor.Author_Notes">
          <title>Author Notes</title>
          <p>Molecular Otolaryngology and Renal Research Laboratories <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://morl.lab.uiowa.edu/about-us">Web page</ext-link></p>
        </sec>
        <sec id="bor.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The original preparation of this manuscript was supported in part by grants 1RO1DC02842 and 1RO1DC03544. (RJHS)</p>
        </sec>
        <sec id="bor.Author_History">
          <title>Author History</title>
          <p>Glenn E Green, MD; Arizona Health Sciences Center (1999-2001)Sai D Prasad; University of Iowa (1999-2001)Richard JH Smith, MD (1999-present)</p>
        </sec>
        <sec id="bor.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>22 October 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>20 June 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>27 August 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>27 March 2008 (cd) Revision: sequence analysis for BOR2-related <italic toggle="yes">SIX5</italic> available clinically</p>
            </list-item>
            <list-item>
              <p>24 March 2006 (cd) Revision: prenatal testing for <italic toggle="yes">EYA1</italic> mutations available</p>
            </list-item>
            <list-item>
              <p>24 January 2006 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>30 October 2003 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>28 November 2001 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 March 1999 (pb) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>6 January 1999 (rjhs) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
